Literature DB >> 9427608

HIV-1 Vpr increases viral expression by manipulation of the cell cycle: a mechanism for selection of Vpr in vivo.

W C Goh1, M E Rogel, C M Kinsey, S F Michael, P N Fultz, M A Nowak, B H Hahn, M Emerman.   

Abstract

The human immunodeficiency virus type 1 (HIV-1) encodes a protein, called Vpr, that prevents proliferation of infected cells by arresting them in G2 of the cell cycle. This Vpr-mediated cell-cycle arrest is also conserved among highly divergent simian immunodeficiency viruses, suggesting an important role in the virus life cycle. However, it has been unclear how this could be a selective advantage for the virus. Here we provide evidence that expression of the viral genome is optimal in the G2 phase of the cell cycle, and that Vpr increases virus production by delaying cells at the point of the cell cycle where the long terminal repeat (LTR) is most active. Although Vpr is selected against when virus is adapted to tissue culture, we show that selection for Vpr function in vivo occurs in both humans and chimpanzees infected with HIV-1. These results suggest a novel mechanism for maximizing virus production in the face of rapid killing of infected target cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9427608     DOI: 10.1038/nm0198-065

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  231 in total

1.  A lentivirus packaging system based on alternative RNA transport mechanisms to express helper and gene transfer vector RNAs and its use to study the requirement of accessory proteins for particle formation and gene delivery.

Authors:  N Srinivasakumar; F G Schuening
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

2.  Modulation of HIV-1 replication by a novel RhoA effector activity.

Authors:  L Wang; H Zhang; P A Solski; M J Hart; C J Der; L Su
Journal:  J Immunol       Date:  2000-05-15       Impact factor: 5.422

3.  Efficient DNA transfection mediated by the C-terminal domain of human immunodeficiency virus type 1 viral protein R.

Authors:  A Kichler; J C Pages; C Leborgne; S Druillennec; C Lenoir; D Coulaud; E Delain; E Le Cam; B P Roques; O Danos
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

4.  Functional role of residues corresponding to helical domain II (amino acids 35 to 46) of human immunodeficiency virus type 1 Vpr.

Authors:  S P Singh; B Tomkowicz; D Lai; M Cartas; S Mahalingam; V S Kalyanaraman; R Murali; A Srinivasan
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

5.  Human immunodeficiency virus type 1 Vpr-mediated G(2) cell cycle arrest: Vpr interferes with cell cycle signaling cascades by interacting with the B subunit of serine/threonine protein phosphatase 2A.

Authors:  M Hrimech; X J Yao; P E Branton; E A Cohen
Journal:  EMBO J       Date:  2000-08-01       Impact factor: 11.598

Review 6.  Strategies in subversion: de-regulation of the mammalian cell cycle by viral gene products.

Authors:  C Swanton; N Jones
Journal:  Int J Exp Pathol       Date:  2001-02       Impact factor: 1.925

7.  Nuclear export of human immunodeficiency virus type 1 Vpr is not required for virion packaging.

Authors:  Y Jenkins; P V Sanchez; B E Meyer; M H Malim
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

8.  Human immunodeficiency virus type 1 Vpr contains two leucine-rich helices that mediate glucocorticoid receptor coactivation independently of its effects on G(2) cell cycle arrest.

Authors:  M P Sherman; C M de Noronha; D Pearce; W C Greene
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

9.  Impairment of human immunodeficiency virus type 1 (HIV-1) entry into Jurkat T cells by constitutive expression of the HIV-1 vpr protein: role of CD4 down-modulation.

Authors:  L Conti; B Varano; M C Gauzzi; P Matarrese; M Federico; W Malorni; F Belardelli; S Gessani
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

10.  Proliferating cellular nuclear antigen expression as a marker of perivascular macrophages in simian immunodeficiency virus encephalitis.

Authors:  Kenneth Williams; Annette Schwartz; Sarah Corey; Marlene Orandle; William Kennedy; Brendon Thompson; Xavier Alvarez; Charlie Brown; Suzanne Gartner; Andrew Lackner
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.